Navigation Links
Jennerex Publishes Promising Results from Cancer Clinical Trial of JX-594 in Lancet Oncology
Date:5/21/2008

to what we predicted based on extensive lab testing of JX-594. This peer-reviewed publication in a Lancet journal represents a major advance for JX-594 and the rest of our pipeline," said David Kirn, M.D., President & CEO of Jennerex. "We especially want to express our extreme gratitude to the doctors, the patients and their families, and our partners at Green Cross who have all pioneered this treatment with us."

Dr. B. G. Rhee, Executive Vice President, Corporate Development at Green Cross, said "Based on these promising clinical results with our partners at Jennerex, we are in the process of opening the Phase II liver cancer trial at world-renowned liver cancer hospitals in South Korea." Jennerex collaborated closely with medical and scientific research teams in South Korea at Dong-A University and Pusan National University Hospitals, and at the Ottawa Health Research Institute, Ottawa, Canada.

Phase I-II Liver Cancer Study

As reported in the Lancet Oncology publication, 14 patients with a variety of treatment-refractory cancer types (e.g. liver, colon, lung) in the liver were treated every three weeks with JX-594 by ultrasound-guided intratumoral injection. Patients had advanced cancers that had failed all available therapies and were therefore considered terminal. Treatment was well-tolerated during dose-escalation up to the maximum-tolerated dose, with the expected mild to moderate flu-like symptoms; no severe toxicities due to treatment were reported up to these doses. Cancer destruction and objective evidence for efficacy were reported in the majority of patients, including all three with primary liver cancer and patients with lung and colon cancers. Tumor responses were achieved in evaluable patients by objective criteria including RECIST (Response Evaluation Criteria in Solid Tumor) (response in 30 percent of patients, stable disease in 60 percent of patients) and Choi criteria (response in 80% of patients). Tumor responses were associ
'/>"/>

SOURCE Jennerex
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Jennerex Presents Clinical Data From JX-594 Demonstrating Tumor Efficacy Against Advanced Liver Cancers
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. The Lancet Publishes Major Phase 3 Study on Novel Oral Direct Thrombin Inhibitor
4. The New England Journal of Medicine Publishes First Clinical Results for MedImmunes Chitinase-like Protein YKL-40 in Patients With Asthma
5. Biological Psychiatry Publishes Study Showing VYVANSE Demonstrated Significant Efficacy for Treatment of ADHD for up to 12 Hours After Administration
6. Franklin & Seidelmann Publishes Complex Podiatry MRI Study
7. Circulation Publishes Data Showing KYNAPID(TM) (Vernakalant Hydrochloride) Injection Rapidly Converted Short-Duration Atrial Fibrillation to Sinus Rhythm
8. ImQuest Publishes Results of Important Structure Activity Relationship Program on Dual Acting Pyrimidinediones
9. Video: The Journal, Human Genetics, Publishes Results Supporting Interleukin Genetics Heart Health Test
10. Promising Cystic Fibrosis Compound on Track for Development
11. Kiadis Pharma Announces Promising Phase II Clinical Trial Results for Reviroc
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 MultiCell Technologies, Inc. (OTC ... U.S. provisional patent application concerning composition of matter, biological ... targeted tumor cell death.  This patent ... double stranded RNA molecules (VSRNAs) which interfere with the ...
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com announces ... available in its catalogue: ... Forecast and Market Analysis to 2022 ... Atopic Dermatitis - India Drug Forecast and ...
(Date:1/15/2014)... , Jan. 15, 2014  A novel wearable injector slightly larger ... painless for patients to self-inject prescription drugs in the large ... cancer, blood diseases, autoimmune deficiencies, and genetic disorders.  ... to $220B by 2018, according to analysts.   Many of these ...
Breaking Medicine Technology:MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2
... today announced that Jeff Abbey , the ... of its Arcelis™ dendritic cell-based immunotherapy at 3:30 ... Conference in New York. In addition, Charles ... president of research and development, will participate in a panel ...
... 18 URAC, a leading independent health care quality ... (MRM) program the Bronze Award in Health Information/Decision Support ... Empowerment and Protection Awards. The awards honor programs that ... The Oklahoma Health Care Authority (OHCA) and Oklahoma Department ...
Cached Medicine Technology:Argos Therapeutics to Present Overview of its Arcelis™ Dendritic Cell-based Immunotherapy, Participate in Panel Discussion at Inaugural Cancer Immunotherapy Conference 2Health Care Coordination Program Honored With URAC National Best Practices Award 2Health Care Coordination Program Honored With URAC National Best Practices Award 3Health Care Coordination Program Honored With URAC National Best Practices Award 4
(Date:4/18/2014)... ― A new study in the American Journal ... Google searches reveals a recurring pattern that could be ... Investigators from San Diego State University, the Santa Fe ... "healthy" Google searches (searches that included the term healthy ... the U.S. from 2005 to 2012. They found that ...
(Date:4/17/2014)... variant specifically associated with the risk of a ... cent of all breast cancer cases. , The ... called invasive lobular carcinoma, gives researchers important clues ... of breast cancer, which can be missed through ... the journal PloS Genetics , was co-led ...
(Date:4/17/2014)... Researchers at the University of California, San Diego School ... those who have suffered a recent major loss are ... older adults. , The study is published in this ... Psychiatry . , Because compassionate behaviors are associated with ... findings offer insights into ways to improve the outcomes ...
(Date:4/17/2014)... 2014U.S. military personnel who served in Iraq and ... brain injury (TBI) were compared to military personnel ... reasons. Differences in measures of overall disability, cognitive ... injury are reported in an article in ... Mary Ann Liebert, Inc., publishers. The article is ...
(Date:4/17/2014)... By discovering a new mechanism that allows blood ... at UC Irvine and the Salk Institute have opened ... prevent stroke-induced brain damage. , A complex and devastating ... and primary reason for disability in the U.S. The ... lets blood-borne material into the brain, causing the permanent ...
Breaking Medicine News(10 mins):Health News:New research shows people are thinking about their health early in the week 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 3Health News:The ilk of human kindness 2Health News:Long-term effects of battle-related 'blast plus impact' concussive TBI in US military 2Health News:Study IDs new cause of brain bleeding immediately after stroke 2
... Association of California Nurse Leaders Supports Research Efforts ... AMN Healthcare congratulates Tanya Osborne-McKenzie, RN, who was ... the 31st annual Association of California Nurse Leaders ... by ACNL. Osborne-McKenzie is the director of ...
... 26 Digital Power Corporation (NYSE Amex: DPW ... and for the year ended December 31, 2008.Digital Power reported ... 3l, 2008, compared to net income of $235,000 for the ... for the fourth quarter of 2008, compared to operating income ...
... SCIENTIST: A GUIDE TO RESPONSIBLE CONDUCT IN RESEARCH, THIRD ... Academy of Engineering, and Institute of Medicine, offers researchers ... on the ethical conduct of scientific research. ... to help readers consider how to respond in complex ...
... Specialized Leases from Elekta Facilitate Sharing of Financial ... health systems are facing a "perfect storm" as ... layoffs and federal cuts, and investment income dwindles. ... from other medical facilities, but from new entrants ...
... Coast Independent Review Board (IRB), testified today before the Subcommittee ... Committee in the Rayburn House Office Building. Coast IRB ... clandestine sting operation at the request of the Committee. ... Coast had committed any crime. No crime was unearthed ...
... to aid in recognizing, treating rare but real condition ... about the symptoms and outcomes of a relatively rare ... been collected by U.S. researchers into a registry of ... 70 people in the new registry -- nearly all ...
Cached Medicine News:Health News:Tanya Osborne-McKenzie Wins AMN Healthcare ACNL Scholarship 2Health News:Digital Power Reports Financial Results for the Fourth Quarter and the Year Ended December 31, 2008 2Health News:Digital Power Reports Financial Results for the Fourth Quarter and the Year Ended December 31, 2008 3Health News:Digital Power Reports Financial Results for the Fourth Quarter and the Year Ended December 31, 2008 4Health News:New Focus Placed on Alternative Financing as Hospitals Seek Competitive Advantage During Challenging Economic Conditions 2Health News:New Focus Placed on Alternative Financing as Hospitals Seek Competitive Advantage During Challenging Economic Conditions 3Health News:Coast IRB Tells Congressional Committee Sting Operation Was Illegal, Unnecessarily Harmful 2Health News:Registry Created for Broken Heart Syndrome 2
... Triiodothyronine (T3) is produced primarily by ... Within the thyroid gland, T3 production occurs ... than that for T4. Release of T3 ... is ~5-8 micrograms/day as compared to 80-100 ...
... Human Insulin-like growth factor binding protein-3 (IGFBP-3) is ... in postnatal serum, as a component of the ... IGFBP-3, a molecule of IGF-I or IGF-II and ... the actions of the IGFs. The molar concentration ...
... a monomeric protein produced and stored in ... is released from the pituitary into the ... regulatory control of hypothalamic somatostatin (SS) and ... frequency of GH release appears to be ...
... is a monomeric protein produced and stored ... GH is released from the pituitary into ... the regulatory control of hypothalamic somatostatin (SS) ... and frequency of GH release appears to ...
Medicine Products: